← SGLT2 inhibitors × glycemic control

TrialDiabetes, obesity & metabolism2015

Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study.

A Kashiwagi et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 168 people · 2015

No range given

Reported lower glycemic control, no range given

−1.30percentage points

As reported

difference −1.30 %, no interval

One number in the abstract

the abstract, start to end

… adjusted mean difference from placebo: -1.30%; p < 0.001).

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
Glycemic control
−1.30
SGLT2 inhibitorsGlycemic control

SGLT2 inhibitors × glycemic controlhelps?replicated

unlikelylikely
0.920.92 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

57 papers cite it

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 24919820